Literature DB >> 26363288

The long journey of botulinum neurotoxins into the synapse.

Andreas Rummel1.   

Abstract

Botulinum neurotoxins (BoNT) cause the disease botulism, a flaccid paralysis of the muscle. They are also very effective, widely used medicines applied locally in sub-nanogram quantities. BoNTs are released together with several non-toxic, associated proteins as progenitor toxin complexes (PCT) by Clostridium botulinum to become highly potent oral poisons ingested via contaminated food. They block the neurotransmission in susceptible animals and humans already in nanogram quantities due to their specific ability to enter motoneurons and to cleave only selected neuronal proteins involved in neuroexocytosis. BoNTs have developed a sophisticated strategy to passage the gastrointestinal tract and to be absorbed in the intestine of the host to finally attack neurons. A non-toxic non-hemagglutinin (NTNHA) forms a binary complex with BoNT to protect it from gastrointestinal degradation. This binary M-PTC is one component of the bi-modular 14-subunit ∼760 kDa large progenitor toxin complex. The other component is the structurally and functionally independent dodecameric hemagglutinin (HA) complex which facilitates the absorption on the intestinal epithelium by glycan binding. Subsequent to its transcytosis the HA complex disrupts the tight junction of the intestinal barrier from the basolateral side by binding to E-cadherin. Now, the L-PTC can also enter the circulation by paracellular routes in much larger quantities. From here, the dissociated BoNTs reach the neuromuscular junction and accumulate via interaction with polysialo gangliosides, complex glycolipids, on motoneurons at the neuromuscular junction. Subsequently, additional specific binding to luminal segments of synaptic vesicles proteins like SV2 and synaptotagmin leads to their uptake. Finally, the neurotoxins shut down the synaptic vesicle cycle, which they had exploited before to enter their target cells, via specific cleavage of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins, which constitute the core components of the cellular membrane fusion machinery.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botulinum neurotoxin; E-cadherin; Hemagglutinin; Intestinal barrier; Neuromuscular junction; Progenitor toxin complex; Synaptic vesicle proteins

Mesh:

Substances:

Year:  2015        PMID: 26363288     DOI: 10.1016/j.toxicon.2015.09.009

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  45 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 2.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

3.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

4.  The Use of Botulinum Toxin in the Management of Headache Disorders.

Authors:  Hsiangkuo Yuan; Stephen D Silberstein
Journal:  Handb Exp Pharmacol       Date:  2021

Review 5.  Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Authors:  Claus M Escher; Lejla Paracka; Dirk Dressler; Katja Kollewe
Journal:  Ther Adv Neurol Disord       Date:  2016-11-16       Impact factor: 6.570

6.  Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain.

Authors:  Duarte Machado; Aditya Kumar; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2016-12-15       Impact factor: 4.546

Review 7.  Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.

Authors:  Marco Pirazzini; Cesare Montecucco; Ornella Rossetto
Journal:  Arch Toxicol       Date:  2022-03-25       Impact factor: 6.168

Review 8.  Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2016-04-21       Impact factor: 4.546

9.  Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.

Authors:  Jasmin Weisemann; Daniel Stern; Stefan Mahrhold; Brigitte G Dorner; Andreas Rummel
Journal:  Toxins (Basel)       Date:  2016-05-17       Impact factor: 4.546

10.  Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test.

Authors:  Jasmin Weisemann; Nadja Krez; Uwe Fiebig; Sylvia Worbs; Martin Skiba; Tanja Endermann; Martin B Dorner; Tomas Bergström; Amalia Muñoz; Ingrid Zegers; Christian Müller; Stephen P Jenkinson; Marc-Andre Avondet; Laurence Delbrassinne; Sarah Denayer; Reinhard Zeleny; Heinz Schimmel; Crister Åstot; Brigitte G Dorner; Andreas Rummel
Journal:  Toxins (Basel)       Date:  2015-11-26       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.